SCHEMBL2832897

SCHEMBL2832897

Cc1ccc2[nH]c3c(c2c1)CN(C(=O)OC(C)(C)C)CC3

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.76
PABPC1 P11940 1/20 0.76
ATM Q13315 1/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
BAZ2B Q9UIF8 7/20 0.71
NPC1 O15118 1/20 0.61
ALDH1A1 P00352 7/20 0.59
MAPT P10636 5/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
GAA P10253 4/20 0.59
CASP1 P29466 4/20 0.59
CASP7 P55210 3/20 0.59
USP2 O75604 1/20 0.59
CFTR P13569 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.56
KDM4E B2RXH2 2/20 0.54
HPGD P15428 2/20 0.54
GLA P06280 1/20 0.54
XBP1 P17861 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10127719 0.93 LMNA (0.66) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL13320196 0.92 LMNA (0.65) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL31117423 0.91 LMNA (0.64) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL16441048 0.91 LMNA (0.62) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL31117526 0.89 SIRT2 (0.62) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL30228387 0.89 TRPV1 (0.59) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL409534 0.88 BAZ2B (0.71) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL21114757 0.88 BAZ2B (0.71) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL5104575 0.88 BAZ2B (0.71) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL16140457 0.88 BAZ2B (0.71) LMNAPABPC1ATMSMN1; SMN2BAZ2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3735411-B1 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE AC IMMUNE SA (CH) 2024-07-10 EP disclosed
US-11814378-B2 Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates AC IMMUNE SA (CH) 2023-11-14 US disclosed
EP-3313837-B1 CARBOLINE ANTIPARASITICS ZOETIS SERVICES LLC (US) 2020-09-09 EP disclosed
US-10633383-B2 Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates AC IMMUNE SA (CH) 2020-04-28 US disclosed
WO-2019134978-A1 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE AC IMMUNE SA (CH) 2019-07-11 WO disclosed
US-20190211012-A1 Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates AC IMMUNE SA (CH) 2019-07-11 US disclosed
US-20100125085-A1 PYRIDOINDOLE MODULATORS OF NMDA RECEPTOR AND ACETYLCHOLINESTERASE AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-20 US disclosed
US-20100125085-A1 PYRIDOINDOLE MODULATORS OF NMDA RECEPTOR AND ACETYLCHOLINESTERASE AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-20 US disclosed
US-20100125085-A1 PYRIDOINDOLE MODULATORS OF NMDA RECEPTOR AND ACETYLCHOLINESTERASE AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-20 US disclosed
WO-2010057104-A2 PYRIDOINDOLE MODULATORS OF NMDA RECEPTOR AND ACETYLCHOLINESTERASE AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
WO-2010057104-A2 PYRIDOINDOLE MODULATORS OF NMDA RECEPTOR AND ACETYLCHOLINESTERASE AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190211012-A1 Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates MAPT, MAP1LC3A, MAP1LC3B LMNA 2338/4885PABPC1 1632/4885ATM 514/4885
US-10633383-B2 Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates MAPT, MAP1LC3A, TUBB3 LMNA 2017/4885PABPC1 1767/4885ATM 527/4885
US-20100125085-A1 PYRIDOINDOLE MODULATORS OF NMDA RECEPTOR AND ACETYLCHOLINESTERASE GRIN3A, GRIK5, CHRNA5 LMNA 3662/4885PABPC1 4237/4885ATM 2317/4885
US-11814378-B2 Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates MAPT, MAP1LC3A, TUBB3 LMNA 2017/4885PABPC1 1767/4885ATM 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.